Concept · medicine
Hepatocellular carcinoma
Follow Hepatocellular carcinoma — see important new research and changes in evidence.Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Rewordings are not listed.
- Concept page published
Hepatocellular carcinoma is the main primary liver cancer. Study layers here separate three claims: tumour EZH2 mRNA as a clinicopathological invasion marker, DNA methylation signatures that classify HCC tissue and track clinical correlates, and preclinical exosome delivery of miR-122 to sensitize HCC models to chemotherapy.
Students collapse “HCC biomarkers” and “HCC therapy ideas” into one story. A surgical expression association, an epigenetic classifier, and a mouse/cell chemosensitisation strategy answer different questions. Mixing them invents false agreement about diagnosis and treatment readiness.
Evidence
What the evidence shows
Drawn from 3 studies in this library. Each finding starts with a plain-language takeaway, then the denser detail. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope with a short note on each study’s contribution. Challenged positions are labeled — they are not findings.
Higher tumour EZH2 mRNA associates with portal-vein invasion after HCC resection.
In 66 surgical HCC tumours, EZH2 mRNA exceeded matched nontumour liver and high expression tracked portal-vein invasion (79% vs 39%) without a significant disease-free survival split — a clinicopathological progression signal, not a proven survival assay in this cohort.
- DNA methylation signatures separate HCC from nearby liver— different molecular layer — promoter methylation signatures, not EZH2 mRNA invasion associations
- miR-122 exosomes from fat stem cells sensitize HCC models to chemo— different question — preclinical chemosensitisation, not surgical clinicopathology
Study Role Design N Population Outcome Higher tumour EZH2 tracks portal-vein invasion in HCC Supports CohortSurgical HCC series; tumour vs nontumour EZH2 mRNA by RT-PCR N=66 · Median-split high vs low tumour expression (n=33 each) Surgical hepatocellular carcinoma patients with tumour and matched nontumour liver EZH2 expression vs portal-vein invasion and disease-free survival DNA methylation signatures separate HCC from nearby liver Qualifiesdifferent molecular layer — promoter methylation signatures, not EZH2 mRNA invasion associations OtherPromoter methylation bead-array discovery in paired tumour/surrounding tissue with independent validation series N=30 · Discovery: 30 HCC tumours with matched surrounding tissue (38 patients selected; 30 with paired samples) Surgical HCC patients at Edouard Herriot Hospital (Lyon) with cryopreserved tumour tissue Methylation signatures distinguishing HCC and correlating with risk factors/survival miR-122 exosomes from fat stem cells sensitize HCC models to chemo Qualifiesdifferent question — preclinical chemosensitisation, not surgical clinicopathology Animal / in-vitromiR-122–loaded AMSC exosomes in HepG2 cells and HepG2 xenografts with chemotherapy In-vitro assays reported with n=3 replicates; xenograft group sizes not a single primary analytic N in stored text HepG2 hepatocellular carcinoma cells and nude-mouse xenografts Chemosensitivity and xenograft tumour response with miR-122 exosomes Validated DNA methylation signatures can separate HCC from surrounding liver.
Illumina promoter arrays in 30 paired HCC/surrounding samples produced a validated methylation signature that distinguished tumour from adjacent liver independent of major risk factors, with other panels linked to progression and survival after therapy.
- Higher tumour EZH2 tracks portal-vein invasion in HCC— related HCC progression theme, but single-gene mRNA vs multi-CpG epigenetic classifier
Study Role Design N Population Outcome DNA methylation signatures separate HCC from nearby liver Supports OtherPromoter methylation bead-array discovery in paired tumour/surrounding tissue with independent validation series N=30 · Discovery: 30 HCC tumours with matched surrounding tissue (38 patients selected; 30 with paired samples) Surgical HCC patients at Edouard Herriot Hospital (Lyon) with cryopreserved tumour tissue Methylation signatures distinguishing HCC and correlating with risk factors/survival Higher tumour EZH2 tracks portal-vein invasion in HCC Qualifiesrelated HCC progression theme, but single-gene mRNA vs multi-CpG epigenetic classifier CohortSurgical HCC series; tumour vs nontumour EZH2 mRNA by RT-PCR N=66 · Median-split high vs low tumour expression (n=33 each) Surgical hepatocellular carcinoma patients with tumour and matched nontumour liver EZH2 expression vs portal-vein invasion and disease-free survival AMSC exosomes can deliver miR-122 and sensitise HCC models to chemotherapy.
miR-122–loaded adipose MSC exosomes raised miR-122 in HepG2 cells, downregulated resistance-linked targets (including CCNG1/ADAM10/IGF1R), and increased chemosensitivity in vitro and in xenograft combinations — a preclinical strategy, not a finished patient protocol.
- Higher tumour EZH2 tracks portal-vein invasion in HCC— human surgical association study, not an exosome therapy experiment
Study Role Design N Population Outcome miR-122 exosomes from fat stem cells sensitize HCC models to chemo Supports Animal / in-vitromiR-122–loaded AMSC exosomes in HepG2 cells and HepG2 xenografts with chemotherapy In-vitro assays reported with n=3 replicates; xenograft group sizes not a single primary analytic N in stored text HepG2 hepatocellular carcinoma cells and nude-mouse xenografts Chemosensitivity and xenograft tumour response with miR-122 exosomes Higher tumour EZH2 tracks portal-vein invasion in HCC Qualifieshuman surgical association study, not an exosome therapy experiment CohortSurgical HCC series; tumour vs nontumour EZH2 mRNA by RT-PCR N=66 · Median-split high vs low tumour expression (n=33 each) Surgical hepatocellular carcinoma patients with tumour and matched nontumour liver EZH2 expression vs portal-vein invasion and disease-free survival
Open questions
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes — limits on how far one study travels — not a forced fight between papers.
EZH2 marks invasion risk in resected human tumours; methylation signatures classify tissue epigenetically; miR-122 exosomes test a delivery/chemosensitisation idea in models. Shared HCC context does not make them one biomarker or one therapy.
- Higher tumour EZH2 tracks portal-vein invasion in HCC
- DNA methylation signatures separate HCC from nearby liver
- miR-122 exosomes from fat stem cells sensitize HCC models to chemo
Study Role Design N Population Outcome Higher tumour EZH2 tracks portal-vein invasion in HCC Supports CohortSurgical HCC series; tumour vs nontumour EZH2 mRNA by RT-PCR N=66 · Median-split high vs low tumour expression (n=33 each) Surgical hepatocellular carcinoma patients with tumour and matched nontumour liver EZH2 expression vs portal-vein invasion and disease-free survival DNA methylation signatures separate HCC from nearby liver Supports OtherPromoter methylation bead-array discovery in paired tumour/surrounding tissue with independent validation series N=30 · Discovery: 30 HCC tumours with matched surrounding tissue (38 patients selected; 30 with paired samples) Surgical HCC patients at Edouard Herriot Hospital (Lyon) with cryopreserved tumour tissue Methylation signatures distinguishing HCC and correlating with risk factors/survival miR-122 exosomes from fat stem cells sensitize HCC models to chemo Supports Animal / in-vitromiR-122–loaded AMSC exosomes in HepG2 cells and HepG2 xenografts with chemotherapy In-vitro assays reported with n=3 replicates; xenograft group sizes not a single primary analytic N in stored text HepG2 hepatocellular carcinoma cells and nude-mouse xenografts Chemosensitivity and xenograft tumour response with miR-122 exosomes EZH2’s invasion association without a DFS split is a different clinical claim from methylation panels that correlate with survival after therapy — both can be true without interchangeable cutoffs.
- Higher tumour EZH2 tracks portal-vein invasion in HCC
- DNA methylation signatures separate HCC from nearby liver
Study Role Design N Population Outcome Higher tumour EZH2 tracks portal-vein invasion in HCC Supports CohortSurgical HCC series; tumour vs nontumour EZH2 mRNA by RT-PCR N=66 · Median-split high vs low tumour expression (n=33 each) Surgical hepatocellular carcinoma patients with tumour and matched nontumour liver EZH2 expression vs portal-vein invasion and disease-free survival DNA methylation signatures separate HCC from nearby liver Supports OtherPromoter methylation bead-array discovery in paired tumour/surrounding tissue with independent validation series N=30 · Discovery: 30 HCC tumours with matched surrounding tissue (38 patients selected; 30 with paired samples) Surgical HCC patients at Edouard Herriot Hospital (Lyon) with cryopreserved tumour tissue Methylation signatures distinguishing HCC and correlating with risk factors/survival
Common misconceptions
Any HCC molecular marker is ready to guide the same treatment decision.
Invasion-linked mRNA, tissue methylation classifiers, and preclinical miRNA delivery answer different questions. None automatically becomes a universal treatment rule.
Higher EZH2 always means worse survival after HCC surgery.
In this cohort it tracked portal-vein invasion, but disease-free survival did not differ significantly between high and low EZH2 groups.
miR-122 AMSC exosomes are an approved HCC chemo adjunct.
Evidence is preclinical (HepG2/xenograft). Authors frame a treatment strategy; patient RCTs and delivery/safety work remain required.
Exam-style questions
Short-answer questions that ask you to explain or compare, not recall.
Why can an EZH2 invasion association and a methylation tumour-vs-liver signature both be useful without being one test?
One links a single transcript to a pathological invasion feature in resected tumours; the other is a multi-CpG epigenetic classifier of tissue identity/clinical correlates. Different molecular layers and decision uses.
A student treats the miR-122 exosome paper as proof patients should receive MSC exosomes with sorafenib tomorrow. What limit blocks that leap?
The work is preclinical cell/xenograft chemosensitisation. Exosome-only tumour control was not significant vs vehicle in the cited comparison, and human dosing/safety/efficacy trials are still required.
The studies
3 studies in this library bear on Hepatocellular carcinoma, ordered by citations.
- miR-122 exosomes from fat stem cells sensitize HCC models to chemo
Adipose MSC exosomes loaded with miR-122 delivered the microRNA into HepG2 cells, downregulated CCNG1/ADAM10/IGF1R, and increased chemosensitivity in vitro and in xenografts combined with agents such as sorafenib.
- Higher tumour EZH2 tracks portal-vein invasion in HCC
In 66 resected HCC tumours, EZH2 mRNA was higher than in paired nontumour liver and high expression associated with portal-vein invasion (79% vs 39%), without a significant disease-free survival difference.
- DNA methylation signatures separate HCC from nearby liver
Promoter methylation arrays in 30 HCC tumours vs surrounding tissue produced a validated signature that distinguished HCC from adjacent liver (independent of major risk factors), with other methylation panels tracking risk factors, progression, and survival after therapy.
Learn alongside